PreOmics is a spin-off from the Max Planck Institute of Biochemistry in Munich. PreOmics develops and distributes consumables and equipment to enable non-experts to use mass spectrometry-based proteomics in drug development, diagnostics, and research. In the future, PreOmics aims to establish MS-based proteomics in personalized medicine and clinical laboratories.
Facts
Contact
2016
Founding year
Stage
Company location
PreOmics GmbH
Am Klopferpsitz 19
82152 Martinsried
[AdditionalInfo]
[Fundings] [Analytics] [Insights]
You might also be interested in
Deals
Preomics raises 3.3 million euros
With an investment of over three million euros, Preomics successfully concludes its Series A financing round. The BioM startup attracted investors, along with several business…
Needs Review
PreOmics receives license for proteomics technology
The Munich-based startup PreOmics has licensed several technologies from the Max Planck Institute of Biochemistry in Martinsried for sample preparation for proteomics research from Max Planck Innovation. In particular…
News
PreOmics wins 2nd prize at Science4Life Award
The BioM startup PreOmics, based at the IZB Martinsried, secured second place at the Science4Life Venture Cup 2016, which was endowed with 10,000 euros.…
